PropThink: ACOR Off on Potential For Tighter Prescribing Rules for Ampyra

PropThink: ACOR Off on Potential For Tighter Prescribing Rules for Ampyra

[ACN Newswire] – US, Oct 8, 2012 – (ACN Newswire) – Acorda Therapeutics (NASDAQ:ACOR) is trading down Monday on circulation of the September 2012 Formulary Decision Highlights from GroupHealth, a healthcare coordination … more

View todays social media effects on ACOR

View the latest stocks trending across Twitter. Click to view dashboard

Share this post